


PRODUCT: BII B021**ALTERNATE NAME:** 6-Chloro-9-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-9H-purin-2-amine; CNF2024**CATALOG #:** 2291-5, 25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C₁₄H₁₅ClN₆O**MOLECULAR WEIGHT:** 318.76**CAS NUMBER:** 848695-25-0**APPEARANCE:** White to off-white solid**SOLUBILITY:** DMSO (~65 mg/ml) or Ethanol (~3 mg/ml)**PURITY:** ≥99% by HPLC**STORAGE:** At -20° C. Protect from light and moisture**DESCRIPTION:** A synthetic, small molecule Hsp90 inhibitor that binds competitively with geldanamycin in the ATP-binding pocket of Hsp90. In tumor cells, BII B021 induces the degradation of Hsp90 client proteins including HER-2, AKT, and Raf-1 and up-regulates expression of the heat shock proteins Hsp70 and Hsp27. BII B021 inhibits the proliferation of N87, MCF-7, and BT474 tumor cells with IC₅₀ values of 0.06, 0.31, and 0.14 μM, respectively.**REFERENCE:** Lundgren, K., *et al.* (2009). *Mol. Cancer Ther.* **8**, 921-929.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

17-AAG (Cat. No. 1774-1,5)

17-DMAG (Cat. No. 1776-1, 5)

Geldanamycin (Cat. No. 1564-1,5)

NVP-AUY922 (Cat. No. 1591-1, 5)

USAGE: *FOR RESEARCH CH USE ONLY! Not to be used in humans*